An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register

Femke H. M. Prince*, Esther W. de Bekker-Grob, Marinka Twilt, Marion A. J. van Rossum, Esther P. A. H. Hoppenreijs, Rebecca ten Cate, Yvonne Koopman-Keemink, Simone L. Gorter, Hein Raat, Lisette W. A. van Suijlekom-Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1131-1136
Issue number6
Publication statusPublished - Jun 2011


  • Juvenile idiopathic arthritis
  • Paediatric rheumatology
  • National register study
  • Etanercept
  • Tumour necrosis factor-alpha
  • Biologic
  • Treatment costs
  • Cost-effectiveness
  • Cost-utility
  • Health utilities index

Cite this